Executive Moves: RWJBarnabas, Atlantic Health and more

    Executive Moves is an occasional feature on ROI-NJ.com describing some of the important personnel changes in the New Jersey business community. Reports are based on news releases, edited for content, clarity and style.

    Dr. Seth D. Cohen, RWJBarnabas Health

    Board-certified internal medicine physician and medical oncologist Dr. Seth D. Cohen has been appointed to the newly created position of regional director of oncology services for the RWJBarnabas Health Southern Region. In this role, Cohen will provide leadership and direction to enhance the quality and future growth of cancer services across Monmouth and Ocean counties, including integrating services available at Monmouth Medical Center, Monmouth Medical Center Southern Campus and Community Medical Center.

    Prior to accepting this position, Cohen served as the medical director for oncology clinical research at Monmouth Medical Center and Monmouth Medical Center Southern Campus, and remains the principal investigator for several oncology clinical trials. As regional director of oncology services for the Southern Region, Cohen will utilize his clinical trials expertise to build and integrate an oncology clinical research program for the entire Southern Region.

    “Dr. Cohen’s clinical expertise and leadership experience make him highly qualified for this critical new role within the Oncology Service Line and the Southern Region,” stated Dr. Steven K. Libutti, senior vice president, oncology services, RWJBarnabas Health, and director, Rutgers Cancer Institute of New Jersey. “As the state’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute in collaboration with RWJBarnabas Health provides the most advanced treatment options for patients close to home including those therapies that come as a result of clinical research.”

    Lisa McFarlane, Atlantic Health System

    As the importance of testing continues to grow in the fight against the COVID-19 pandemic, Atlantic Health System, a leading provider of health care in New Jersey, has named board-certified clinical laboratory scientist Lisa McFarlane as its new director of laboratory services.

    McFarlane takes the reins of Atlantic Health System’s laboratory services, which serves the organization’s seven hospitals, multiple ancillary sites and physician network of nearly 1,000 providers, all linked by a team of laboratory couriers, as well as phlebotomists who provide outreach services. The laboratory services include the Atlantic Consolidated Laboratory, which provides a robust array of services, processing more than 16,000 tests each day for a variety of conditions.

    McFarlane is a member of the American Society of Clinical Pathology and comes to Atlantic Health System with 15 years of experience in both pathology and laboratory operations, most recently from Hackensack University Medical Center, where she served as the technical and operations director of the laboratory.

    Narayan Bharadwaj, Indecomm Global Services

    Indecomm Global Services, a leading provider of automation, outsourcing and compliance services and technology for the U.S. mortgage industry, announced that Narayan Bharadwaj has joined the company as senior vice president of automation.

    In this role, Bharadwaj is responsible for automation strategy and execution with a goal of transforming the operations and technology landscape of the mortgage industry. He reports to Rajan Nair, CEO of Indecomm.

    (Not pictured.)

    Todd Branning, Phathom Pharmaceuticals Inc.

    Phathom Pharmaceuticals Inc., a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced that it has appointed Todd Branning as chief financial officer. Interim CFO David Socks will continue with the company as a strategic adviser and remain a member of the board of directors.

    Branning was most recently with Amneal Pharmaceuticals Inc., where he served as senior vice president and chief financial officer. He brings a diverse global finance background consisting of over 25 years of experience in corporate finance and accounting, tax, financial planning and analysis, and investor relations.

    (Not pictured.)

    Centenary University

    Three area business leaders have been named to four-year terms on the Centenary University board of trustees, announced Wolfgang Gstattenbauer, board chair.

    The new trustees are:

    • Lester Aron, an experienced legal and business adviser to educational, corporate and government clients, and the former director of the New Jersey Office of Employee Relations.
    • Michael J. Gulotta, founder and CEO of Deo Volente Farms, a world-class breeding center for standardbreds located in Flemington;
    • Jill Kracov Zinckgraf, executive director and CEO of the Domestic Abuse and Sexual Assault Crisis Center of Warren County;

    (Not pictured.)

    Dr. Myron S. Czuczman, Citius Pharmaceuticals

    Citius Pharmaceuticals Inc., a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced that Dr. Myron S. Czuczman has joined the company as chief medical officer and executive vice president.

    Dr. Czuczman was most recently therapeutic area head, vice president, clinical research and development, global lymphoma/CLL program at Celgene Corp. At Celgene, he was responsible for worldwide clinical development in Lymphoma/CLL and for the development of all compounds from Proof-of-Principle through registration globally.

    Bud Jones, Nisivoccia

    Nisivoccia, a leading accounting and business advisory firm, is pleased to announce that Bud Jones has been named managing partner of the firm, succeeding Timothy Mehaffey. Jones becomes the fourth managing partner of Nisivoccia as the firm celebrates its 50-year anniversary.

    “As managing partner, I look forward to overseeing the future growth of the firm, strengthening our unparalleled firm culture and working with our professionals to continue to exceed our clients’ expectations,” he said.

    (Not pictured.)

    Richard Laverty, Critical Response Group Inc.

    Critical Response Group Inc. announced that Richard Laverty, former deputy branch commander for investigations of the New Jersey State Police, will lead its public safety implementation efforts. Laverty’s 26-year career included command assignments at the training academy, as a troop commander overseeing field operations in central and southern New Jersey and commanding officer of New Jersey’s Regional Operations Intelligence Center, the state’s fusion center.

    “Public safety professionals across the country are encountering uncommon challenges where increased situational awareness is critical to their success. Our company realizes the importance of supporting CRG clients and their use of our products in these times, and feel Rich is perfectly suited to lead that effort across the country,” said Phil Coyne, president of CRG. “His extensive background in emergency operations, training and policy development make him uniquely qualified to assume the role of director of implementation.”

    (Not pictured.)

    N.J. Association of Ambulatory Surgery Centers

    The New Jersey Association of Ambulatory Surgery Centers has elected members to its board of directors. They are: Bonnie Brady Lavoie, West Morris Surgery; Joan McKibben,Ambulatory Surgical Center of Somerset; and Caroline Ivanovski-Hauser, Bergen-Passaic Eye Surgery Center, who will also serve as NJAASC’s treasurer.

    “NJAASC has a very proactive and engaged board that has been committed to not only supporting our members, but all (centers) in New Jersey,” explained NJAASC President Jeff Shanton. “NJAASC has been extremely active since the COVID-19 pandemic hit New Jersey in helping to guide centers through the crisis, while serving as a liaison to the (Department of Health) and as an industry voice in the Governor’s Office. I know that these new board members will continue to serve the organization well, and we look forward to working with them.”

    (Not pictured.)

    Chris Venezia, TrialScope

    TrialScope, the global leader in clinical trial transparency, has hired Chris Venezia as chief commercial officer, expanding its executive team.

    Much of Venezia’s career has been focused on pharmaceutical and health care technologies. A frequent speaker and trainer, he served as chief revenue officer of Signals Analytics. Prior to that, he worked in global sales at both Clarivate Analytics and Thomson Reuters, and served as vice president of sales at GlobalData plc.

    (Not pictured.)